Photo courtesy of ASCO/Todd Buchanan 2016. “The Bean” or Cloud Gate with a little ASCO color, highlighting the 2016 ASCO Annual Meeting, which took place in Chicago, June 3-7.
 ASCOBrian Powers.jpg)
Treatment dose and schedule, as well as a patient’s tumor burden, influence the outcome of therapy with chimeric antigen receptor (CAR) T cells, according to research presented at the 2016 ASCO Annual Meeting. One presentation suggested the dose and schedule... [Read Article]
 ASCOTodd Buchanan.jpg)
Lenalidomide maintenance after high-dose melphalan and autologous stem cell transplant (ASCT) should be considered the standard of care in newly diagnosed multiple myeloma (MM) patients, according to a meta-analysis presented at the 2016 ASCO Annual Meeting.... [Read Article]
Nearly 60% of chronic myeloid leukemia (CML) patients who switch to nilotinib from imatinib maintain treatment-free remission for 48 weeks after stopping treatment, according to a new study, ENESTop, presented at the 2016 ASCO Annual Meeting.Treatment-free remission... [Read Article]
 ASCOZach Boyden-Holmes.jpg)
Investigators have found an increased risk in cancer incidence for patients with primary immunodeficiency diseases (PIDD), and in particular, a significant increase in lymphoma cases. Investigators reviewed records of patients registered in the United States Immune Deficiency... [Read Article]
A phase 3 study of tandem autologous stem cell transplant (ASCT) for children with high-risk neuroblastoma has shown that tandem transplant as consolidation significantly improved event-free survival (EFS). Nevertheless, the improvement comes “with an important caveat,” according to Julie R. Park, MD, “that this is in children... [Read Article]
Investigators are pursuing the combination of the selective BCL-2 inhibitor venetoclax plus low-dose cytarabine (LDAC) in older, treatment-naïve patients with acute myeloid leukemia (AML) who are unfit for intensive chemotherapy. These patients have few treatment... [Read Article]
The first interim analysis of rituximab plus chemotherapy in children and adolescents with high-risk B-cell non-Hodgkin lymphoma (B-NHL) and acute leukemia has yielded results that “will change our clinical practice,” according to Veronique Minard-Colin, MD, PhD, one of... [Read Article]
The addition of the monoclonal antibody daratumumab to bortezomib and dexamethasone, the current standard of care for relapsed/refractory multiple myeloma (MM), has achieved progression-free survival that is “unprecedented in randomized studies that compared novel treatment” for this disease, according to Antonio Palumbo, MD, lead author of the phase... [Read Article]
Hispanic white and non-Hispanic black adolescents and young adults (AYA) are more likely to die of their disease than the same-aged white patients, according to a study presented at the 2016 ASCO Annual Meeting. If the chance of a young-adult white patient dying within 2 years... [Read Article]
An interim analysis of a large, phase 3 study has confirmed that upfront autologous stem cell transplantation (ASCT) is still the preferred treatment for newly diagnosed, young multiple myeloma (MM) patients, even in the age of novel agents such as bortezomib. Investigators compared 4 cycles of bortezomib-melphalan-prednisone (VMP)... [Read Article]
